Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes

Journal of Perinatology volume 36, pages 544–548 (2016)Cite this article

Subjects

Abstract

OBJECTIVE:

Enteral feeds are often discontinued or reduced during indomethacin treatment for patent ductus arteriosus (PDA) in preterm neonates, but the clinical impact of this practice is unknown. The objective of this study was to study the associations between enteral feed volume at the time of indomethacin therapy in preterm neonates with PDA and subsequent gastrointestinal outcomes.

STUDY Design:

Retrospective cohort study. Single-center level III Neonatal Intensive Care Unit.

RESULTS:

All consecutive preterm neonates who had received treatment with indomethacin for PDA over a 5-year period were included and categorized based on enteral feed volume exposure during treatment (Group A: nil per oral (NPO, N=229); Group B: ⩽60 ml kg−1 day−1 (N=142); Group C:>60 ml kg−1 day−1 (N=44)). Baseline characteristics and clinical outcomes were compared between the three groups. The primary outcome was necrotizing enterocolitis (NEC) ⩾stage IIa, while secondary outcomes included other gastrointestinal complications and common prematurity-related morbidities. Group C had a higher gestational age (mean±s.d.; A: 26.3±1.8; B: 26.1±1.8; C: 27.0±2.0 weeks), birth weight (A: 864±239; B: 847±202; C: 932±234 g) and postnatal age at the time of indomethacin treatment (A: 5.3±2.9; B: 7.2±4.9; C: 15.4±6.6 days). All groups had similar rates of the primary outcome NEC (A: 6.1%, B: 7.8% and C: 4.6%, respectively). They also had similar rates of the secondary outcomes with the exception of days to reach enteral feeds of 120 ml kg−1 day−1 (A: 22.8±8.5; B: 20.5±8.6; C: 16.8±7.7; P<0.05 for all inter-group comparisons). Secondary analysis including only those neonates who were not already NPO before indomethacin treatment (N=261) and categorized based on preemptive management (made NPO; enteral feed volume reduced; enteral feed volume unchanged/increased) also showed similar results.

Conclusions:

This large retrospective study did not identify any association between enteral feed volumes during indomethacin treatment or preemptive reduction in enteral feeds and subsequent incidence of adverse gastrointestinal outcomes in preterm neonates. Preemptive reduction in enteral feed volume was associated with longer time to reach full enteral feeds.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. McCurnin D, Clyman RI . Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics 2008; 122: e1262–e1267.

    Article  Google Scholar 

  2. Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS . Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child 1990; 65: 1067–1071.

    Article  CAS  Google Scholar 

  3. Laudignon N, Chemtob S, Bard H, Aranda JV . Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988; 54: 254–262.

    Article  CAS  Google Scholar 

  4. Christmann V, Liem KD, Semmekrot BA, van de Bor M . Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002; 91: 440–446.

    Article  CAS  Google Scholar 

  5. Fowlie PW, Davis PG, McGuire W . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Syst Rev 2010, Issue 7. Art. No.: CD000174. doi:10.1002/14651858.CD000174.pub2.

  6. Jhaveri N, Soll RF, Clyman RI . Feeding practices and patent ductus arteriosus ligation preferences-are they related? Am J Perinatol 2010; 27: 667–674.

    Article  Google Scholar 

  7. Clyman R, Wickremasinghe A, Jhaveri N, Hassinger DC, Attridge JT, Sanocka U et al. Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus. J Pediatr 2013; 163 (2): 406–411. e4.

    Article  CAS  Google Scholar 

  8. Fenton TR, Kim JH . A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013; 13: 59.

    Article  Google Scholar 

  9. Kliegman RM . Neonatal necrotizing enterocolitis: implications for an infectious disease. Pediatr Clin North Am 1979; 26: 327–344.

    Article  CAS  Google Scholar 

  10. Jobe AH, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723–1729.

    Article  CAS  Google Scholar 

  11. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991–999.

    Article  Google Scholar 

  12. Kelleher J, Salas AA, Bhat R, Ambalavanan N, Saha S, Stoll BJ et al. Prophylactic indomethacin and intestinal perforation in extremely low birth weight infants. Pediatrics 2014; 134: e1369–e1377.

    Article  Google Scholar 

  13. Yanowitz TD, Reese J, Gillam-Krakauer M, Cochran CM, Jegatheesan P, Lau J et al. Superior mesenteric artery blood flow velocities following medical treatment of a patent ductus arteriosus. J Pediatr 2014; 164: 661–663.

    Article  Google Scholar 

  14. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF . Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733–738.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Junmin Yang, statistician in Mother and Infant Care Program of Mount Sinai Hospital, Toronto, ON, Canada for performing the statistical analysis for this study and Josie Chundamala, scientific editor at Mother and Infant Care Program of Mount Sinai Hospital, Toronto, ON, Canada for proofreading the manuscript.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Mount Sinai Hospital, Toronto, ON, Canada

    D Louis, R Torgalkar, J Shah & A Jain

  2. Department of Pediatrics and Health Policy, Management, and Evaluation, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

    P S Shah

Authors
  1. D Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Torgalkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P S Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Jain.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Louis, D., Torgalkar, R., Shah, J. et al. Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes. J Perinatol 36, 544–548 (2016). https://doi.org/10.1038/jp.2016.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2016.11

This article is cited by

Search

Advanced search

Quick links